Search Results

Biovica International Biovica, active in blood-based cancer monitoring, has signed a master service agreement with a biopharmaceutical company enabling Biovica to provide its TKa testing assay and testing services.

Biovica International Biovica has received a positive International Preliminary Report on Patentability covering the use of TKa as a prognostic and monitoring marker in cancer treatment outside the CDK 4/6 inhibitor space, expanding the market potential for the DiviTum TKa technology by four to six times.

Biovica International Biovica, active in blood-based cancer monitoring, announces a cost reduction program in Sweden and the US that will result in annual cost savings of approximately SEK 30 million and a restructuring cost of SEK 8 million.

Biovica International Biovica, active in blood-based cancer monitoring, has signed a master service agreement with a leading tier-1 pharmaceutical company, enabling Biovica to provide its TKa testing assay and testing services.

Biovica International The Nomination Committee prior to the 2024 Annual General Meeting will consist of three members, who shall represent the two shareholders with the highest number of shares who accept the assignment to be part of the Nomination Committee as of December 31, 2023, and the Chairman of the Board.

Biovica International Biovica, active in cancer diagnostics, announces that the company has received a license for Maryland state, the 18th largest state in the US.

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, active in cancer monitoring, has signed a collaboration agreement for DiviTum® TKa in Spain and Portugal with the Palex Group, a leading hospital equipment supplier with a proven track record in taking oncology tests and surgical instruments to market in southern Europe.

Biovica International publishes its interim report for the second quarter 2023/2024, on November 28 at 08:00 CET.

Biovica International announces that the company has signed a commercial partnership agreement for the Nordics with Axlab A/S to commercialize the DiviTum® TKa assay.

Biovica International Biovica, active in cancer monitoring, announces the signing of an agreement providing access to DiviTum TKa to appropriate patients treated at a leading cancer center in Florida.